Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$18.62 - $26.95 $196,813 - $284,861
10,570 New
10,570 $198 Million
Q1 2023

May 10, 2023

BUY
$37.27 - $46.57 $537,135 - $671,166
14,412 New
14,412 $605 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.